Kennedy Capital Management LLC Raises Stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Kennedy Capital Management LLC grew its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 113.8% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 267,355 shares of the medical device company's stock after acquiring an additional 142,321 shares during the period. Kennedy Capital Management LLC owned 0.41% of Tandem Diabetes Care worth $9,630,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Capital Fund Management S.A. increased its stake in shares of Tandem Diabetes Care by 116.1% in the fourth quarter. Capital Fund Management S.A. now owns 200,277 shares of the medical device company's stock valued at $7,214,000 after buying an additional 107,587 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Tandem Diabetes Care in the fourth quarter worth $5,893,000. Renaissance Technologies LLC increased its position in shares of Tandem Diabetes Care by 50.0% during the 4th quarter. Renaissance Technologies LLC now owns 315,727 shares of the medical device company's stock worth $11,372,000 after purchasing an additional 105,300 shares during the last quarter. FIL Ltd lifted its stake in Tandem Diabetes Care by 48.7% in the 4th quarter. FIL Ltd now owns 201,376 shares of the medical device company's stock valued at $7,254,000 after purchasing an additional 65,984 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in shares of Tandem Diabetes Care by 4.3% during the 4th quarter. Bank of Montreal Can now owns 10,004 shares of the medical device company's stock worth $360,000 after buying an additional 409 shares during the period.

Insiders Place Their Bets

In other news, COO Jean-Claude Kyrillos purchased 10,538 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, March 7th. The shares were acquired at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the transaction, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 2.20% of the company's stock.

Tandem Diabetes Care Stock Down 2.5 %

Shares of NASDAQ:TNDM traded down $0.45 on Wednesday, reaching $17.26. The company had a trading volume of 588,311 shares, compared to its average volume of 1,499,571. The stock has a 50-day moving average price of $22.85 and a 200 day moving average price of $30.55. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The stock has a market capitalization of $1.15 billion, a P/E ratio of -8.94 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Analyst Ratings Changes

A number of analysts have commented on the stock. Mizuho assumed coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a "neutral" rating and a $20.00 price target on the stock. The Goldman Sachs Group dropped their price objective on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Citigroup cut shares of Tandem Diabetes Care from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $35.00 to $24.00 in a report on Tuesday, March 4th. Canaccord Genuity Group restated a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a report on Wednesday, February 26th. Finally, Royal Bank of Canada decreased their price objective on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating on the stock in a research report on Thursday, February 27th. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $43.88.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.